Access cutting-edge venous thromboembolism treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access venous thromboembolism specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related venous thromboembolism treatment provided free
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Sponsor: Anthos Therapeutics, Inc.
Check if you qualify for this venous thromboembolism clinical trial in Washington Dc, DC
If you're searching for venous thromboembolism treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced venous thromboembolism specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.